@article{5d9aa8156a0944a4be1a6666edd06010,
title = "Use of GLP-1 Ras in cardiovascular disease prevention: A practical guide",
keywords = "Cardiovascular death, Cardiovascular disease, Cardiovascular event reduction, GLP-1 RA, Type 2 diabetes mellitus",
author = "Ildiko Lingvay and Leiter, {Lawrence A.}",
note = "Funding Information: Dr Lingvay has received research grants from GI Dynamics, Merck, Novartis, Novo Nordisk, and Pfizer; other research support from Astra Zeneca, Boehringer Ingelheim, Novo Nordisk, and Sanofi; and honoraria from Astra Zeneca, Int-arcia, Novo Nordisk, and Sanofi. Dr Leiter has received research funding from, provided Continuous Medical Education on behalf of, or acted as an adviser to AstraZeneca, Boehringer Ingelheim, Eli Lilly, GSK, Janssen, Merck, Novo Nordisk, Sanofi, and Servier.",
year = "2018",
doi = "10.1161/CIRCULATIONAHA.117.032759",
language = "English (US)",
volume = "137",
pages = "2200--2202",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "21",
}